Skip to main content

Table 4 Adjusted odds ratios for FN in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively (Broad Definition of FN)

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

 

Adjusted Odds Ratio for FN (95% CI, p-value)*

Cycle 1

Cycle 2

Cycles ≥3

Last Cycle

All Cycles

Commercial

 Independent Variables

  No PEG Prophylaxis

2.6 (2.3–2.8, < 0.001)

1.9 (1.6–2.2, < 0.001)

1.5 (1.4–1.7, < 0.001)

1.5 (1.4–1.7, < 0.001)

2.1 (2.0–2.3, < 0.001)

  FN in Prior Cycle

–

3.2 (2.6–3.9, < 0.001)

3.5 (3.2–4.0, < 0.001)

2.4 (2.0–2.8, < 0.001)

2.4 (2.2–2.6, < 0.001)

  Regimen

   TAC

2.9 (2.6–3.3, < 0.001)

2.6 (1.7–4.1, < 0.001)

1.7 (1.4–1.9, < 0.001)

3.3 (2.4–4.8, < 0.001)

2.7 (2.2–3.2, < 0.001)

   TC

–

–

–

–

–

   TCH

1.1 (1.0–1.2, 0.229)

2.2 (1.4–3.3, < 0.001)

1.1 (1.0–1.2, 0.266)

2.1 (1.5–2.9, < 0.001)

1.4 (1.2–1.6, < 0.001)

   CHOP±R

1.3 (1.2–1.5, < 0.001)

4.1 (1.9–9.0, < 0.001)

1.7 (1.5–1.9, < 0.001)

4.3 (2.4–7.7, < 0.001)

2.6 (1.9–3.5, < 0.001)

  Age

   18–49

–

–

–

–

–

   50–64

1.0 (0.9–1.1, 0.377)

1.0 (0.9–1.2, 0.884)

1.1 (1.0–1.2, 0.242)

1.3 (1.1–1.4, 0.002)

1.0 (1.0–1.1, 0.409)

   65–74

1.3 (1.2–1.5, < 0.001)

1.0 (0.8–1.2, 0.881)

1.5 (1.3–1.8, < 0.001)

1.7 (1.4–2.1, < 0.001)

1.3 (1.2–1.4, < 0.001)

   ≥ 75

1.7 (1.4–2.1, < 0.001)

1.2 (0.9–1.7, 0.200)

2.1 (1.8–2.6, < 0.001)

3.4 (2.7–4.3, < 0.001)

1.7 (1.5–2.0, < 0.001)

Medicare

 Independent Variables

  No PEG Prophylaxis

1.6 (1.5–1.7, < 0.001)

1.6 (1.5–1.8, < 0.001)

1.3 (1.3–1.4, < 0.001)

1.0 (0.9–1.0, 0.507)

1.5 (1.4–1.5, < 0.001)

  FN in Prior Cycle

–

3.2 (2.9–3.5, < 0.001)

2.9 (2.7–3.1, < 0.001)

1.7 (1.6–1.8, < 0.001)

2.1 (2.1–2.2, < 0.001)

  Regimen

   TAC

2.5 (2.2–2.9, < 0.001)

1.9 (1.5–2.4, < 0.001)

2.0 (1.7–2.3, < 0.001)

2.2 (1.9–2.6, < 0.001)

2.1 (1.9–2.3, < 0.001)

   TC

–

–

–

–

–

   TCH

0.8 (0.7–0.9, < 0.001)

0.9 (0.8–1.0, 0.127)

0.8 (0.7–0.9, < 0.001)

1.0 (0.9–1.2, 0.387)

0.8 (0.7–0.8, < 0.001)

   CHOP±R

1.5 (1.4–1.5, < 0.001)

1.8 (1.7–2.0, < 0.001)

1.9 (1.8–2.0, < 0.001)

1.8 (1.7–2.0, < 0.001)

1.6 (1.6–1.7, < 0.001)

  Age

   65–74

–

–

–

–

–

   75–84

1.2 (1.1–1.3, < 0.001)

1.0 (0.9–1.1, 0.709)

1.1 (1.1–1.2, < 0.001)

1.2 (1.1–1.3, < 0.001)

1.1 (1.1–1.2, < 0.001)

   ≥ 85

1.4 (1.3–1.5, < 0.001)

1.2 (1.1–1.4, < 0.001)

1.4 (1.3–1.5, < 0.001)

1.8 (1.6–1.9, < 0.001)

1.4 (1.3–1.4, < 0.001)

  1. FN febrile neutropenia, PEG pegfilgrastim, TC docetaxel + cyclophosphamide, TAC docetaxel + doxorubicin + cyclophosphamide, TCH docetaxel + cyclophosphamide + trastuzumab, CHOP cyclophosphamide + doxorubicin + vincristine + prednisone, R, rituximab
  2. *Adjusted for other characteristics of patients listed in Table 1; additional covariates selected via backward selection method